Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.10 USD
Change Today -0.91 / -11.36%
Volume 20.2M
OREX On Other Exchanges
Symbol
Exchange
Stuttgart
As of 8:10 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

orexigen therapeutics inc (OREX) Key Developments

Orexigen Therapeutics, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Orexigen Therapeutics, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the three months ended December 31, 2014, the company reported a net profit of $0.6 million, or $0.00 per basic and diluted share, as compared to a net loss of $21.5 million, or $0.21 per basic and diluted share, for the fourth quarter of 2013. Total revenues were $22,950,000 compared to $857,000 a year ago. Income from operations was $2,385,000 compared to loss from operations of $20,956,000 a year ago. For the year ended December 31, 2014, the company reported a net loss of $37.5 million, or $0.32 per basic and diluted share, as compared to a net loss of $77.7 million, or $0.80 per basic and diluted share, for 2013. Total revenues were $55,521,000 compared to $3,428,000 a year ago. Loss from operations was $30,530,000 compared to $77,198,000 a year ago.

Orexigen Therapeutics, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 01:35 PM

Orexigen Therapeutics, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 01:35 PM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Michael A. Narachi, Chief Executive Officer, President and Director.

Orexigen Therapeutics, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015

Orexigen Therapeutics, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

Orexigen Therapeutics, Inc. to Report Q4, 2014 Results on Feb 25, 2015

Orexigen Therapeutics, Inc. announced that they will report Q4, 2014 results at 9:00 AM, Eastern Standard Time on Feb 25, 2015

Orexigen Therapeutics, Inc., Q4 2014 Earnings Call, Feb 25, 2015

Orexigen Therapeutics, Inc., Q4 2014 Earnings Call, Feb 25, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OREX:US $7.10 USD -0.91

OREX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OREX.
View Industry Companies
 

Industry Analysis

OREX

Industry Average

Valuation OREX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.7x
Price/Book 44.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXIGEN THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.